$CC News

Chemours Announces Dates for Third Quarter 2026 Earnings Release and Webcast Conference Call

How Patent Battles At Chemours (CC) Have Changed Its Investment Story

Truist Securities Maintains Buy on Chemours, Lowers Price Target to $20

Chemours and Local Officials Take Action to Protect Refrigerant Intellectual Property at Chillventa

Chemours: The Current Trajectory Is Not Reflective Of The Upside

Mizuho Downgrades Chemours to Neutral from Outperform

Mizuho Downgrades Chemours to Neutral, Lowers Price Target to $15

Barclays Initiates Coverage of Chemours at Equal-Weight

Chemours Could Face Headwinds in Thermal & Specialized Solutions Segment Until Year-End, RBC Says

Chemours falls as RBC downgrades stock on persistent TiO2 weakness

Barclays Initiates Coverage On Chemours with Equal-Weight Rating, Announces Price Target of $16

Chemours Q2 2026 Earnings Call: Complete Transcript

UBS Maintains Neutral on Chemours, Lowers Price Target to $16

Mizuho Maintains Outperform on Chemours, Lowers Price Target to $18

Are Options Traders Betting on a Big Move in Chemours Stock?

Chemours (CC) Trims Losses While Core Demand Keeps Slipping

Chemours, DuPont, Corteva settle North Carolina PFAS claims for $455M

Chemours, DuPont, Corteva reach $455 PFAS settlement with North Carolina

Why Is Chemours Stock Trading Higher Today?

Chemours, DuPont De Nemours And Corteva Reach Settlement State Of North Carolina And 11 Local Entities; Overall Settlement Payments Total $455M Over 15 Years, With Chemours' 50% Share Of Payments Of ~$180M On NPV Basis Covered By Existing Accruals